Prevalence of abnormal levels of serum tumour markers in elderly people

Age and Ageing

Volumn 25, Issue 1, 1996, Pages 45-50

  Lopez, Luis A ^a,d   Del Villar, Valentin ^a   Ulla, Mariano ^a   Fernandez, Francisco ^b   Fernandez, Luis A ^a   Santos, Idelfonso ^a   Rabadan, Luis ^a   Gutierrez, Martin ^c  

^a Hospital General del Insalud Soria   (Spain)

^b Residencia El Parque   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^d NONE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CA 72-4 ANTIGEN; CARBOHYDRATE ANTIGEN; CARCINOEMBRYONIC ANTIGEN; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADULT; AGED; AGING; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; FEMALE; HUMAN; INSTITUTIONAL CARE; MALE; PREVALENCE; PRIORITY JOURNAL;

EID: 0030025809     PISSN: 00020729     EISSN: None     Source Type: Journal    
DOI: 10.1093/ageing/25.1.45     Document Type: Article

References (53)

1. Kennedy BJ. Aging and cancer. J Clin Oncol 1988;6:1903-11.
2. Lonergan ET, Krevans JR. A national agenda for research on aging: special report. N Engl J Med 1991;324:1825-8.
3. Instituto Nacional de Estadistica. Población segin la edad (grupos quinquenales) Censo de población. 1 de Marzo de 1991.
4. Newell GR, Spitz MR, Sider JG. Cancer and age. Semin Oncol 1989;16:3-9.
5. Yancik R, Ries LG. Epidemiological features of cancer in the elderly. In: Zenser TV, Coe RM, eds. Cancer and aging. New York: Springer, 1989;3-18.
6. Ries LA, Hankey BF, Edwards BK. Cancer statistics: review, 1973-87. National Cancer Institute, Division of Cancer Prevention and Control, Surveillance Program 1990; NIH publication 90-2789. Bethesda.
7. Makuch RW, Muenz LR. Evaluating the adequacy of tumor markers to discriminate among distinct populations. Semin Oncol 1987;14:89-101.
8. Bates SE. Clinical applications of serum tumor markers. Ann Intern Med 1991;115:623-38.
9. Galen RS. When is a tumor marker a laboratory test? Ann Clin Lab Sci 1977;7:51-6.
10. Kennedy BJ. Needed: clinical trials for older patients. J Clin Oncol 1991;5:718-19.
11. Fentiman IS, Tirelli U, Monfardini S, et al. Cancer in the elderly: why so badly treated? Lancet 1990; i: 1020-2.
12. Miller RA. Gerontology as oncology. Cancer 1991;68:2496-501.
13. Mettlin C, Bonfiglio J, Berg RL, et al. Prevention and detection in older persons. Cancer 1991;68:2530-3.
14. Cavalieri TA, Chopra A, Bryman PN. When outside the norm is normal: interpreting lab data in the aged. Geriatrics 1992;47:66-70.
15. Filella X, Cases A, Molina R, et al. Tumor markers in patients with chronic renal failure. Int J Biol Markers. 1990;5:85-8.
16. Odagiri E, Jibiki K, Takeda M, et al. Effect of hemodialysis on the concentration of the seven tumor markers carcinoembryonic antigen, alpha-fetoprotein, squamous cell carcinoma-related antigen, neuron-specific enolase, CA 125, CA 19-9 and CA 15-3 in uremic patients. Am J Nephrol 1991;11:363-8.
17. Berardi RS, Ruiz R, Becknell WE, Keonin Y. Does advanced age limit the usefulness of CEA assays? Geriatrics 1977;32:86-8.
18. Fletcher RH. Carcinoembryonic antigen. Ann Intern Med 1986;104:66-73.
19. Stevens DP, Mackay IR, Cullen KJ. Carcinoembryonic antigen in an unselected elderly population: a four year follow up. Br J Cancer 1975;32:147-51.
20. Touitou Y, Proust J, Klinger E, Nakache JP, Huarda D, Sachet A. Cumulative effects of age and pathology on plasma carcinoembryonic antigen in an unselected elderly population. Eur J Cancer Clin Oncol 1984;20:369-74.
21. Del Villano BC, Brennan S, Brock P, et al. Radio-immunometric assay for a monoclonal antibody-defined tumor marker Ca 19-9. Clin Chem 1983;29:549-52.
22. Haves DF, Zurawski VR, Kufe DW. Comparison of circulating CA 15-3 and CEA levels in patients with breast cancer. J Clin Oncol 1986;4:1542-50.
23. Klug TL, Sattler MA, Colcher D, Scholm J. Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA 72) on a novel pancarcinoma antigen (TAG-72). Int J Cancer 1986;661-9.
24. Chayvialle JAP, Ganguili PC. Radioimmunoassay of alpha- fetoprotein in human plasma. Lancet 1973;i:1355-7.
25. Ball D, Rose E, Alpert E. Alpha-fetoprotein levels in normal adults. Am J Med Sci 1992;303:157-9.
26. Masseyeff R, Bonet C, Drouet J, Sudaka P, Lalanne C. Radioimmunoassay of alpha-fetoprotein: I. Techniques and serum levels in the normal adult. Digestion 1974;10:17-28.
27. Trichopoulos D, Sizaret P, Tabor E, et al. Alphafetoprotein levels of liver cancer patients and controls in a European population. Cancer 1980;46:736-40.
28. Drawer MK, Chetner MP, Beatie J, Buchner DM, Vessella RL, Lange PH. Screening for prostatic carcinoma with prostate specific antigen. J Urol 1992;147:841-5.
29. Babaian RJ, Miyashita H, Evans RB, Ramirez EI. The distribution of prostate specific antigen in men without clinical or pathological evidence of prostate cancer: relationship to gland volume and age. J Urol 1992;147:837-40.
30. Gion M, Mione R, Dittadi R, et al. Evaluation of CA 15-3 levels in breast cancer patients, J Nucl Med Allied Sci 1986;30:29-36.
31. Loewenstein MS, Zamchezk N. Carcinoembryonic antigen levels in benign gastrointestinal disease. Cancer 1978;42:1412-18.
32. Mizushima Y, Hirata H, Izumi S, et al. Clinical significance of the number of positive tumor markers in assisting the diagnosis of lung cancer with multiple tumor marker assay. Oncology 1990;47:43-8.
33. Encabo G, Ruibal A. Serum CA 19-9 levels in patients with non-tumoral pathologies: our experience in 892 cases. Bull Cancer (Paris) 1986;73:256-9.
34. Ruibal A, Encabo G, Genollá V, Guarga A, Urrutia A, Colomer R. Serum CA 15-3 levels in patients with general pathology and malignanr diseases. Bull Cancer (Paris) 1986;73:94-5.
35. Ruibal A, Genolla J, Rosell M, Gris JM, Colomer R. Serum CA 15-3 levels in patients with non-tumoral diseases, and establishment of a threshold for tumoral activity. Int J Biol Markers 1986;1:159-60.
36. Kaczynski J, Jagenburg R, Lindstedt G, Wallerstedt S. Markedly increased alpha-fetoprotein concentrations in serum in alcoholic liver disease: malignant tumor or nonneoplastic changes? Clin Chem 1992;38:710-16.
37. Kroon WA, Sánchez de la Muela PL, Berian Polo JM. Antigeno prosiático especifico: utilidad en la práctica clinica. Med Clin (Bare) 1992;98:345-7.
38. Hudson MA, Bahnson RR, Catalona WJ. Clinical use of prostate specific antigen in patients with prostate cancer. J Urol 1989;142:1011-16.
39. Ferro MA, Barnes I, Roberts JBM, Smith PJB. Tumour markers in prostatic carcinoma: a comparison of prostate-specific antigen with acid phosphatase. Br J Urol 1987;60:69-72.
40. Moon TD. The aging prostate. In: Morley JE, Korenman SG, eds. Prostate cancer. Cambridge, Mass.: Blackwell Scientific Publications, 1992:273-93.
41. Martin GM. Proliferative homeostasis and its age-related aberrations. Mech Ageing Dev 1979;9:385-91.
42. Atillasoy E, Holt PR. Gastrointestinal proliferation and aging, J Gerontol 1993;48:B43-9.
43. Nagayo T. Gastric cancer preceded by severe dysplasia. Histol Histopathol 1986;1:171-80.
44. Wei-cheng You, William J, Blot Ji-You Li, et al. Precancerous gastric lesions in a population at high risk of stomach cancer. Cancer Res 1993;53:1317-21.
45. DiSario JA, Foutch PG, Mai HD, Pardy K, Manne RK. Prevalence and malignant potential of colorectal polyps in asymptomatic, average-risk men. Am J Gastroenterol 1991;86:941-5.
46. Kapuller LL, Strekalovskii VP, Khankin SL, Gorbeshlo TP, Gvamichava TA. Hyperplastic changes in the mucosa in colon cancer. Arkh Patol 1991;53:33-7.
47. Suda K, Mogaki M, Oyama T. A comparison between hyperplasia of ductal epithelium and mucin producing tumor of the pancreas. Rinsho Byori 1991;39:1220-4.
48. Takahashi S, Shirai T, Hasegawa R, Imaida K, Ito N. Latent prostatic carcinomas found at autopsy in men over 90 years old. Jpn J Clin Oncol 1992;22:117-21.
49. Inai K, Yamamoto A, Arihiro K, Khatun N, Kurihara K, Takeda S. Epithelial hyperplasia of the breast: comparison of incidence between cases of breast carcinoma and control autopsy specimens with immunohistochemical observation of blood groups antigens. Acta Pathol Jpn 1992;42:193-200.
50. Benhamou PY, Vuillez JP, Halimi S, Meffre G, Bachelot I. Influence of metabolic disturbances of diabetes mellitus on serum CA 19-9 tumor marker. Diabete Metab 1991;17:39-43.
51. Sameshima Y, Chia D, Terasaki PI, Imagawa DK, Busuttil RW. Appearance of the tumor marker CA 19-9 in liver transplant patients during rejection episodes. Transplantation 1992;53:580-2.
52. Bender BS, Nagel JE, Adler WH, Andres R. Absolute peripheral blood lymphocyte count and subsequent mortality of elderly men. J Am Geriatric Soc 1986;34:649-54.
53. Mooradian AD, Reed RL, Osterweil D, Scuderi P. Detectable serum levels of tumor necrosis factor alpha may predict early mortality in elderly institutionalized patients. J Am Geriatric Soc 1991;38:891-4.